XWPharma

XWPharma

Neuroscience biotech developing novel therapeutics for sleep, neuropsych, and other underserved CNS disorders.

Founded 2014

United States 16 employees Series C Total: $57.50M Biotechnology, Health Care +1

XWPharma is a biotech company with a vision to develop groundbreaking therapeutics for a range of underserved CNS disorders. Established in 2014, the company focuses on the development of novel small molecule drug candidates that target neurological and neuropsychiatric disorders and has a global presence. With a commitment to neuroscience and biotechnology, XWPharma is dedicated to addressing unmet medical needs in the field of sleep, neuropsychiatric, and other CNS disorders. The company's pipeline comprises internally discovered drug candidates that show promise in addressing critical neurological and neuropsychiatric conditions. XWPharma's innovative approach and focus on areas that are currently underserved in the field of central nervous system therapeutics positions it as a noteworthy player in the industry. With a track record of pioneering research and development, XWPharma is poised to make a significant impact on the treatment of these complex disorders, potentially transforming patient care and outcomes. As of the latest available information, XWPharma has not disclosed its last investment round or associated investors. This indicates a potential opportunity for venture capital firms seeking to participate in the growth and development of a pioneering biotech company with a focus on neurological and neuropsychiatric therapeutics. With a headquarters in the United States, XWPharma's global reach and strategic focus make it an intriguing prospect for investors looking to contribute to the advancement of treatment options for CNS disorders.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$40.00M	7	CDIB Capital, WuXi Healthcare Ventures +5	18 Sep 2020
Series B	$17.50M	3	WI Harper Group, WuXi Healthcare Ventures +1	20 Sep 2017
Series A	Undisclosed	-		01 Sep 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$40.00M

CDIB Capital, WuXi Healthcare Ventures +5

18 Sep 2020

Series B

$17.50M

WI Harper Group, WuXi Healthcare Ventures +1

20 Sep 2017

Series A

Undisclosed

01 Sep 2014

FAQ About XWPharma

Neuroscience biotech developing novel therapeutics for sleep, neuropsych, and other underserved CNS disorders.

XWPharma was founded in 2014.

XWPharma is headquartered in United States.

XWPharma operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on neuroscience, biotech, CNS disorders and sleep.

XWPharma has approximately 16 employees.

XWPharma has completed 3 funding rounds, raising a total of $57.50M. The latest funding stage is Series C.

Top alternatives and competitors to XWPharma include Proniras Corporation, Psy Therapeutics, Hypnion, Libra Therapeutics, BlackThorn Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

XWPharma and Proniras Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About XWPharma

Funding Rounds & Investors (3)

XWPharma Alternatives & Competitors

FAQ About XWPharma